natgillin/translations-raw huggingface dataset:
1 ml of solution (corresponding to 10 MIU) in a vial (type I glass), with a stopper (halobutyl rubber) in a flipoff seal (aluminium) with a bonnet (polypropylene) with 1 injection syringe, 1 injection needle and 1 cleansing swab. 
1 ml raztopine (kar ustreza 10 milijonom i.e.) v viali (iz stekla tipa I), z zamaškom (iz halobutilne gume) in zaporko s ploščico (iz aluminija) s pokrovčkom (iz polipropilena), z 1 injekcijsko brizgo, 1 injekcijsko iglo in 1 čistilnim tamponom.
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 1 million IU/ml 
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT 1 milijon i.e./ml
Stomatitis ulcerative, right upper quadrant pain, glossitis, gingivitis, constipation, loose stools Pancreatitis, ischaemic colitis, ulcerative colitis, gingival bleeding 
ulcerozni stomatitis, bolečine v zgornjem desnem kvadrantu trebuha, glositis, gingivitis, zaprtje, vodeno blato pankreatitis, ishemični kolitis, ulcerozni kolitis, krvavitve iz dlesni periodontalna bolezen NOS, zobna bolezen NOS§
INFORMATION IN BRAILLE Viraferon 5 MIU solution 
PODATKI V BRAILLOVI PISAVI Viraferon 5 mio i.e. raztopina
INFORMATION IN BRAILLE Viraferon 10 MIU solution 
PODATKI V BRAILLOVI PISAVI Viraferon 10 mio i.e. raztopina
Dental and gum disorders, which may lead to loss of teeth, have been reported in patients receiving Viraferon and ribavirin combination therapy. 
Pri bolnikih, ki so prejemali zdravilo Viraferon in ribavirin v kombinirani terapiji, so poročali o zobnih boleznih in boleznih parodoncija, ki lahko vodijo do izgube zob.
PHARMACEUTICAL FORM AND CONTENTS 1 million IU/ml powder and solvent for solution for injection 1 vial of powder, 1 ampoule of solvent, 1 injection syringe, 2 injection needles and 1 cleansing swab 
1 milijon i.e./ml prašek in vehikel za raztopino za injiciranje 1 viala s praškom, 1 ampula z vehiklom, 1 injekcijska brizga, 2 injekcijski igli in 1 čistilni tampon
The active substance is recombinant interferon alfa-2b, 3 million IU/ml. 
- Zdravilna učinkovina je rekombinantni interferon alfa-2b, 3 milijoni i.e./ml.
2.5 ml of solution (corresponding to 25 MIU) in a vial (type I glass), with a stopper (halobutyl rubber) in a flip-off seal (aluminium) with a bonnet (polypropylene). 
2,5 ml raztopine (kar ustreza 25 milijonom i.e.) v viali (iz stekla tipa I), z zamaškom (iz halobutilne gume) in zaporko s ploščico (iz aluminija) s pokrovčkom (iz polipropilena).
MARKETING AUTHORISATION NUMBER(S) EU/1/99/128/004 1 vial of powder EU/1/99/128/005 6 vials of powder 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/99/128/006 1 viala s praškom
QUALITATIVE AND QUANTITATIVE COMPOSITION One vial of Viraferon solution for injection, single dose vial, contains 3 million IU of recombinant interferon alfa-2b produced in E.coli by recombinant DNA technology, in 0.5 ml of solution. 
Ena viala zdravila Viraferon, raztopina za injiciranje v viali z enkratnim odmerkom vsebuje 3 milijone i.e. rekombinantnega interferona alfa-2b pridobljenega iz E. coli s tehnikami rekombinantne DNA tehnologije v 0,5 ml raztopine.
Ocular adverse events (see section 4.8) including retinal haemorrhages, cotton wool spots, and retinal artery or vein obstruction have been reported in rare instance after treatment with alpha interferons. 
V redkih primerih so po zdravljenju z alfa interferoni poročali o očesnih neželenih dogodkih(glejte poglavje 4.8), npr. krvavitvah v mrežnico, bombažu podobnih lisah in zamašitvi mrežnične arterije ali vene.
1.2 ml of solution (corresponding to 30 MIU) in a pen made of a cartridge (type I glass) sealed at one end with an cap (aluminium) containing a liner (bromobutyl rubber) and at the other end by a plunger (bromobutyl rubber) with 12 injection needles and12 cleansing swabs 
1,2 ml raztopine (kar ustreza 30 milijonom i.e.) v peresniku, ki sestoji iz vložka (iz stekla tipa I), zaprtega na enem koncu z zaporko (iz aluminija) z obrobo (iz bromobutilne gume) in na drugem z batom (iz bromobutilne gume), z 12 injekcijskimi iglami in 12 čistilnimi tamponi.
1.2 ml of solution (corresponding to 60 MIU) in a pen made of a cartridge (type I glass) sealed at one end with an cap (aluminium) containing a liner (bromobutyl rubber) and at the other end by a plunger (bromobutyl rubber) with 12 injection needles and12 cleansing swabs 
1,2 ml raztopine (kar ustreza 60 milijonom i.e.) v peresniku, ki sestoji iz vložka (iz stekla tipa I), zaprtega na enem koncu z zaporko (iz aluminija) z obrobo (iz bromobutilne gume) in na drugem z batom (iz bromobutilne gume), z 12 injekcijskimi iglami in 12 čistilnimi tamponi.
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 10 million IU/ml 
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT 10 milijonov i.e./ml
One vial of powder contains 5 million IU of interferon alfa-2b produced in E.coli by recombinant DNA technology. 
Ena viala s praškom vsebuje 5 milijonov i.e. interferona alfa-2b pridobljenega iz E. coli s tehnikami rekombinantne DNA tehnologije.
EU/1/99/128/028 12 multiple dose vials 
EU/1/99/128/028 12 vial z večkratnimi odmerki
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Viraferon 18 million IU/3 ml solution for injection interferon alfa-2b 
IME ZDRAVILA IN POT(I) UPORABE Viraferon 18 milijonov i.e./3 ml raztopina za injiciranje interferon alfa-2b s.c.
After reconstitution, 1 ml contains 1 million IU of interferon alfa-2b. 
Po rekonstituciji 1 ml vsebuje 1 milijon i.e. interferona alfa-2b.
MARKETING AUTHORISATION NUMBER(S) EU/1/99/128/029 1 pen 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/99/128/029 1 peresnik
QUALITATIVE AND QUANTITATIVE COMPOSITION One vial of Viraferon solution for injection, single dose vial, contains 5 million IU of recombinant interferon alfa-2b produced in E.coli by recombinant DNA technology, in 0.5 ml of solution. 
Ena viala zdravila Viraferon, raztopina za injiciranje v viali z enkratnim odmerkom vsebuje 5 milijonov i.e. rekombinantnega interferona alfa-2b pridobljenega iz E. coli s tehnikami rekombinantne DNA tehnologije v 0,5 ml raztopine.
Reconstitution of Viraferon, powder for solution for injection, for parenteral administration: Viraferon is supplied as a powder at strengths of 5 million IU/ml for single-dose use. 
Rekonstitucija zdravila Viraferon, prašek za raztopino za injiciranje za parenteralno uporabo: Zdravilo Viraferon je na voljo v obliki praška z jakostjo 5 milijonov i.e./ml za dajanje v enkratnem odmerku.
After reconstitution, 1 ml contains 3 million IU of interferon alfa-2b. 
Po rekonstituciji 1 ml vsebuje 3 milijone i.e. interferona alfa-2b.
Viraferon, 5 million IU/ml powder and solvent for solution for injection Interferon alfa-2b 
Viraferon 5 milijonov i.e./ml prašek in vehikel za raztopino za injiciranje interferon alfa-2b
The active substance is recombinant interferon alfa-2b, 10 million IU/ml. 
- Zdravilna učinkovina je rekombinantni interferon alfa-2b, 10 milijonov i.e./ml.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Viraferon 25 million IU/2.5 ml solution for injection interferon alfa-2b 
IME ZDRAVILA IN POT(I) UPORABE Viraferon 25 milijonov i.e./2,5 ml raztopina za injiciranje interferon alfa-2b s.c.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Viraferon 5 million IU/ml powder for injection interferon alfa-2b 
IME ZDRAVILA IN POT(I) UPORABE Viraferon 5 milijonov i.e./ml prašek za injekcije interferon alfa-2b s.c.
After reconstitution, 1 ml contains 10 million IU of interferon alfa-2b. 
Po rekonstituciji 1 ml vsebuje 10 milijonov i.e. interferona alfa-2b.
EU/1/99/128/017 1 single dose vial 
EU/1/99/128/017 1 viala z enkratnim odmerkom
Viraferon (3 MIU TIW) + ribavirin (800 mg) 
trikrat na teden) + ribavirin (800 mg)
EU/1/99/128/036 2 pens 
EU/1/99/128/036 2 peresnika
MARKETING AUTHORISATION NUMBER(S) EU/1/99/128/032 1 pen 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/99/128/032 1 peresnik
EU/1/99/128/021 1 multiple dose vial 
EU/1/99/128/021 1 viala z večkratnimi odmerki
Viraferon, 1 million IU/ml powder and solvent for solution for injection Interferon alfa-2b 
Viraferon 1 milijon i.e./ml prašek in vehikel za raztopino za injiciranje interferon alfa-2b
Epistaxis, respiratory disorder, nasal congestion, rhinorrhea, cough nonproductive 
epistaksa, bolezni dihal, zamašen nos, rinoreja, neproduktiven kašelj pljučni infiltrati§, pnevmonitis§
INFORMATION IN BRAILLE Viraferon 30 MIU pen 
PODATKI V BRAILLOVI PISAVI Viraferon 30 mio i.e. peresnik
NAME OF THE MEDICINAL PRODUCT Viraferon 10 million IU/ml powder and solvent for solution for injection 
IME ZDRAVILA Viraferon 10 milijonov i.e./ml., prašek in vehikel za raztopino za injiciranje
QUALITATIVE AND QUANTITATIVE COMPOSITION One cartridge contains 60 million IU of recombinant interferon alfa-2b produced in E.coli by recombinant DNA technology, in 1.2 ml. 
En vložek vsebuje 60 milijonov i.e. rekombinantnega interferona alfa-2b pridobljenega iz E. coli s tehnikami rekombinantne DNA tehnologije v 1,2 ml.
MARKETING AUTHORISATION NUMBER(S) EU/1/99/128/002 1 vial of powder EU/1/99/128/003 6 vials of powder 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/99/128/002 1 viala s praškom
10 million IU/ml powder and solvent for solution for injection 1 vial of powder, 1 ampoule of solvent, 1 injection syringe, 2 injection needles and 1 cleansing swab 6 vials of powder and 6 ampoules of solvent 
10 milijonov i.e./ml prašek in vehikel za raztopino za injiciranje 1 viala s praškom, 1 ampula z vehiklom, 1 injekcijska brizga, 2 injekcijski igli in 1 čistilni tampon 6 vial s praškom in 6 ampul z vehiklom
EU/1/99/128/018 1 single dose vial, 1 injection syringe, 1 injection needle and 1 cleansing swab EU/1/99/128/019 6 single dose vials 
EU/1/99/128/018 1 viala z enkratnim odmerkom, 1 injekcijska brizga, 1 injekcijska igla in 1 čistilni tampon
One ml of solution contains 10 million IU of interferon alfa-2b 
- En ml raztopine vsebuje 10 milijonov i.e. interferona alfa-2b
EU/1/99/128/025 1 multiple dose vial 
EU/1/99/128/025 1 viala z večkratnimi odmerki
EU/1/99/128/024 12 multiple dose vials 
EU/1/99/128/024 12 vial z večkratnimi odmerki
EU/1/99/128/014 1 single dose vial, 1 injection syringe, 1 injection needle and 1 cleansing swab EU/1/99/128/015 6 single dose vials 
EU/1/99/128/014 1 viala z enkratnim odmerkom, 1 injekcijska brizga, 1 injekcijska igla in 1 čistilni tampon
PHARMACEUTICAL FORM AND CONTENTS 5 million IU/ml powder and solvent for solution for injection 1 vial of powder, 1 ampoule of solvent, 1 injection syringe, 2 injection needles and 1 cleansing swab 6 vials of powder and 6 ampoules of solvent 
5 milijonov i.e./ml prašek in vehikel za raztopino za injiciranje 1 viala s praškom, 1 ampula z vehiklom, 1 injekcijska brizga, 2 injekcijski igli in 1 čistilni tampon 6 vial s praškom in 6 ampul z vehiklom
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Viraferon 60 million IU solution for injection multidose pen interferon alfa-2b 
IME ZDRAVILA IN POT(I) UPORABE Viraferon 60 milijonov i.e. raztopina za injiciranje v večodmernem peresniku interferon alfa-2b
0.5 ml of solution (corresponding to 5 MIU) in a vial (type I glass), with a stopper (halobutyl rubber) in a flip-off seal (aluminium) with a bonnet (polypropylene) Pack sizes of 1 
0,5 ml raztopine (kar ustreza 5 milijonom i.e.) v viali (iz stekla tipa I), z zamaškom (iz halobutilne gume) in zaporko s ploščico (iz aluminija) s pokrovčkom (iz polipropilena).
p value a alfa-2b (100 or c µg/week) + ribavirin 
Vrednost p a pegiliran interferon alfa-2b teden) + ribavirin mg)d
EU/1/99/128/033 2 pens 
EU/1/99/128/033 2 peresnika
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Viraferon 3 million IU/ml powder for injection interferon alfa-2b 
IME ZDRAVILA IN POT(I) UPORABE Viraferon 3 milijoni i.e./ml prašek za injekcije interferon alfa-2b s.c.
Interferons may affect the oxidative metabolic process. 
Interferoni lahko povzročijo neobičajno utrujenost.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Viraferon 18 million IU solution for injection multidose pen interferon alfa-2b 
IME ZDRAVILA IN POT(I) UPORABE Viraferon 18 milijonov i.e. raztopina za injiciranje v večodmernem peresniku interferon alfa-2b
One vial of powder contains 3 million IU of interferon alfa-2b produced in E.coli by recombinant DNA technology. 
Ena viala s praškom vsebuje 3 milijone i.e. interferona alfa-2b pridobljenega iz E. coli s tehnikami rekombinantne DNA tehnologije.
Select the injection site. 
Izberite si mesto, kamor boste injicirali zdravilo.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING 
PODATKI NA ZUNANJI OVOJNINI Škatla
24 mg of powder (corresponding to 10 MIU) in a vial (type I glass), with a stopper (butyl rubber) in a flip-off seal (aluminium) with a bonnet (polypropylene) and 1 ml water for injections in an ampoule (type I glass). 
24 mg praška (kar ustreza 10 milijonom i.e.) v viali (iz stekla tipa I), z zamaškom (iz butilne gume) in zaporko s ploščico (iz aluminija) s pokrovčkom (iz polipropilena) in 1 ml vode za injekcije v ampuli (iz stekla tipa I).
MARKETING AUTHORISATION NUMBER(S) EU/1/99/128/035 1 pen 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/99/128/035 1 peresnik
One vial of powder contains 1 million IU of interferon alfa-2b produced in E.coli by recombinant DNA technology. 
Ena viala s praškom vsebuje 1 milijon i.e. interferona alfa-2b pridobljenega iz E. coli s tehnikami rekombinantne DNA tehnologije.
Viraferon, 3 million IU/ml powder and solvent for solution for injection Interferon alfa-2b 
Viraferon 3 milijoni i.e./ml prašek in vehikel za raztopino za injiciranje interferon alfa-2b
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Viraferon 10 million IU/ml powder for injection interferon alfa-2b 
IME ZDRAVILA IN POT(I) UPORABE Viraferon 10 milijonov i.e./ml prašek za injekcije interferon alfa-2b s.c.
Reconstitution of Viraferon, powder for solution for injection, for parenteral administration: Viraferon is supplied as a powder at strengths of 1 million IU/ml for single-dose use. 
Rekonstitucija zdravila Viraferon, prašek za raztopino za injiciranje za parenteralno uporabo: Zdravilo Viraferon je na voljo v obliki praška z jakostjo 1 milijon i.e./ml za dajanje v enkratnem odmerku.
One vial of powder contains 10 million IU of interferon alfa-2b produced in E.coli by recombinant DNA technology. 
Ena viala s praškom vsebuje 10 milijonov i.e. interferona alfa-2b pridobljenega iz E. coli s tehnikami rekombinantne DNA tehnologije.
Pack of 6 vials of powder for solution for injection and 6 ampoules of water for injections Pack of 10 vials of powder for solution for injection, 10 ampoules of water for injections, 10 injection syringes, 20 injection needles and 10 cleansing swabs Not all pack sizes may be marketed. 
Viraferon je na voljo v treh različnih velikostih pakiranja: Pakiranje: 1 viala s praškom za raztopino za injiciranje, 1 ampula vode za injiciranje, 1 injekcijska brizga, 2 injekcijski igli in 1 čistilni tampon Pakiranje: 6 vial s praškom za raztopino za injiciranje, 6 ampul vode za injiciranje - Pakiranje: 10 vial s praškom za raztopino za injiciranje, 10 ampul vode za injiciranje, 10 injekcijskih brizg, 20 injekcijskih igel in 10 čistilnih tamponov Na trgu ni vseh navedenih pakiranj.
Reconstitution of Viraferon, powder for solution for injection, for parenteral administration: Viraferon is supplied as a powder at strengths of 10 million IU/ml for single-dose use. 
Rekonstitucija zdravila Viraferon, prašek za raztopino za injiciranje za parenteralno uporabo: Zdravilo Viraferon je na voljo v obliki praška z jakostjo 10 milijonov i.e./ml., za dajanje v enkratnem odmerku.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Viraferon 3 million IU/0.5 ml solution for injection interferon alfa-2b 
IME ZDRAVILA IN POT(I) UPORABE Viraferon 3 milijoni i.e./0,5 ml raztopina za injiciranje interferon alfa-2b s.c.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Viraferon 30 million IU solution for injection multidose pen interferon alfa-2b 
IME ZDRAVILA IN POT(I) UPORABE Viraferon 30 milijonov i.e. raztopina za injiciranje v večodmernem peresniku interferon alfa-2b
The active substance is recombinant interferon alfa-2b, 5 million IU in a single dose vial The other ingredients are disodium phosphate anhydrous, sodium dihydrogen phosphate monohydrate, edetate disodium, sodium chloride, m-cresol, polysorbate 80 and water for injections. 
Kaj vsebuje zdravilo Viraferon - Zdravilna učinkovina je rekombinantni interferon alfa-2b, 5 milijonov i.e. v viali z enkratnim - Pomožne snovi so brezvodni natrijev hidrogenfosfat, natrijev dihidrogen fosfat monohidrat, natrijev edetat, natrijev klorid, m-krezol, polisorbat 80 in voda za injekcije.
EU/1/99/128/010 1 single dose vial, 1 injection syringe, 1 injection needle and 1 cleansing swab EU/1/99/128/011 6 single dose vials 
EU/1/99/128/010 1 viala z enkratnim odmerkom, 1 injekcijska brizga, 1 injekcijska igla in 1 čistilni tampon
The active substance is recombinant interferon alfa-2b, 10 million IU in a single dose vial The other ingredients are disodium phosphate anhydrous, sodium dihydrogen phosphate monohydrate, edetate disodium, sodium chloride, m-cresol, polysorbate 80 and water for injections. 
Kaj vsebuje zdravilo Viraferon - Zdravilna učinkovina je rekombinantni interferon alfa-2b, 10 milijonov i.e. v viali z enkratnim - Pomožne snovi so brezvodni natrijev hidrogenfosfat, natrijev dihidrogen fosfat monohidrat, natrijev edetat, natrijev klorid, m-krezol, polisorbat 80 in voda za injekcije.
EU/1/99/128/030 2 pens 
EU/1/99/128/030 2 peresnika
Reconstituting Viraferon powder for injection 
FARMACEVTSKA OBLIKA Raztopina za injiciranje.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Viraferon 5 million IU/0.5 ml solution for injection interferon alfa-2b 
IME ZDRAVILA IN POT(I) UPORABE Viraferon 5 milijonov i.e./0,5 ml raztopina za injiciranje interferon alfa-2b s.c.
The active substance is recombinant interferon alfa-2b, 3 million IU in a single dose vial The other ingredients are disodium phosphate anhydrous, sodium dihydrogen phosphate monohydrate, edetate disodium, sodium chloride, m-cresol, polysorbate 80 and water for injections. 
Kaj vsebuje zdravilo Viraferon - Zdravilna učinkovina je rekombinantni interferon alfa-2b, 3 milijoni i.e. v viali z enkratnim - Pomožne snovi so brezvodni natrijev hidrogenfosfat, natrijev dihidrogen fosfat monohidrat, natrijev edetat, natrijev klorid, m-krezol, polisorbat 80 in voda za injekcije.
MARKETING AUTHORISATION NUMBERS EU/1/99/128/006 
ŠTEVILKA (ŠTEVILKE) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/99/128/006
Check with your doctor immediately if any of the following side effects occur: 
Če se pojavi kateri od naslednjih neželenih učinkov, se nemudoma posvetujte s svojim zdravnikom:
Reconstitution of Viraferon, powder for solution for injection, for parenteral administration: Viraferon is supplied as a powder at strengths of 3 million IU/ml for single-dose use. 
Rekonstitucija zdravila Viraferon, prašek za raztopino za injiciranje za parenteralno uporabo: Zdravilo Viraferon je na voljo v obliki praška z jakostjo 3 milijoni i.e./ml., za dajanje v enkratnem odmerku.
MARKETING AUTHORISATION NUMBERS EU/1/99/128/004 
ŠTEVILKA (ŠTEVILKE) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/99/128/004
Viraferon, 10 million IU/ml powder and solvent for solution for injection Interferon alfa-2b 
Viraferon 10 milijonov i.e./ml prašek in vehikel za raztopino za injiciranje interferon alfa-2b
EU/1/99/128/013 1 single dose vial 
EU/1/99/128/013 1 viala z enkratnim odmerkom
NL-3542 DN Utrecht Tel: + 31-(0)800 778 78 78 
Tel: + 31-(0)800 778 78 78
Discontinuation of Viraferon should be considered in patients who develop new or worsening ophthalmological disorders. 
Pri bolnikih, pri katerih se pojavijo nove oftalmološke motnje ali se obstoječe poslabšajo, premislite o prekinitvi zdravljenja z zdravilom Viraferon.
PHARMACEUTICAL FORM AND CONTENTS 3 million IU/ml powder and solvent for solution for injection 1 vial of powder, 1 ampoule of solvent, 1 injection syringe, 2 injection needles and 1 cleansing swab 6 vials of powder and 6 ampoules of solvent 
3 milijoni i.e./ml prašek in vehikel za raztopino za injiciranje 1 viala s praškom, 1 ampula z vehiklom, 1 injekcijska brizga, 2 injekcijski igli in 1 čistilni tampon 6 vial s praškom in 6 ampul z vehiklom
EU/1/99/128/034 8 pens 
EU/1/99/128/034 8 peresnikov
Cap 
SERIJE
MARKETING AUTHORISATION NUMBERS EU/1/99/128/002 
ŠTEVILKA (ŠTEVILKE) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/99/128/002
MARKETING AUTHORISATION NUMBER(S) EU/1/99/128/001 
ŠTEVILKA (ŠTEVILKE) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/99/128/001
24 mg of powder (corresponding to 5 MIU) in a vial (type I glass), with a stopper (butyl rubber) in a flip-off seal (aluminium) with a bonnet (polypropylene) and 1 ml water for injections in an ampoule (type I glass) Pack sizes of 6 
24 mg praška (kar ustreza 5 milijonom i.e.) v viali (iz stekla tipa I), z zamaškom (iz butilne gume) in zaporko s ploščico (iz aluminija) s pokrovčkom (iz polipropilena) in 1 ml vode za injekcije v ampuli (iz stekla tipa I).
24 mg of powder (corresponding to 3 MIU) in a vial (type I glass), with a stopper (butyl rubber) in a flip-off seal (aluminium) with a bonnet (polypropylene) and 1 ml of water for injections in an ampoule (type I glass) Pack sizes of 6 
24 mg praška (kar ustreza 3 milijonom i.e.) v viali (iz stekla tipa I), z zamaškom (iz butilne gume) in zaporko s ploščico (iz aluminija) s pokrovčkom (iz polipropilena) in 1 ml vode za injekcije v ampuli (iz stekla tipa I).
Determine TSH levels if, during the course of Viraferon therapy, a patient develops symptoms consistent with possible thyroid dysfunction. 
Če se pri bolniku med zdravljenjem z zdravilom Viraferon pojavijo simptomi, ki kažejo na morebitne motnje delovanja žleze ščitnice, določite koncentracijo TSH.
§, hyperuricemia, increased appetite Hypertriglyceridemia 
anoreksija hipertrigliceridemija§, hiperurikemija, povečan tek
24 mg of powder (corresponding to 5 MIU) in a vial (type I glass), with a stopper (butyl rubber) in a flip-off seal (aluminium) with a bonnet (polypropylene) and 1 ml water for injections in an ampoule (type I glass) with 1 injection syringe, 2 injection needles and 1 cleansing swab. 
24 mg praška (kar ustreza 5 milijonom i.e.) v viali (iz stekla tipa I), z zamaškom (iz butilne gume) in zaporko s ploščico (iz aluminija) s pokrovčkom (iz polipropilena) in 1 ml vode za injekcije v ampuli (iz stekla tipa I), z 1 injekcijsko brizgo, 2 injekcijskima iglama in 1 čistilnim tamponom.
Within its shelf-life, for the purpose of transport, the solution can be kept at or below 25ºC for a period up to seven days before use. 
V času roka uporabnosti pri prevozu lahko raztopino pred uporabo shranjujete pri temperaturi do vključno 25°C do 7 dni.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Viraferon 10 million IU/ml solution for injection interferon alfa-2b 
IME ZDRAVILA IN POT(I) UPORABE Viraferon 10 milijonov i.e./ml raztopina za injiciranje interferon alfa-2b s.c.
24 mg of powder (corresponding to 3 MIU) in a vial (type I glass), with a stopper (butyl rubber) in a flip-off seal (aluminium) with a bonnet (polypropylene) and 1 ml of water for injections in an ampoule (type I glass) with 1 injection syringe, 2 injection needles and 1 cleansing swab. 
24 mg praška (kar ustreza 3 milijonom i.e.) v viali (iz stekla tipa I), z zamaškom (iz butilne gume) in zaporko s ploščico (iz aluminija) s pokrovčkom (iz polipropilena) in 1 ml vode za injekcije v ampuli (iz stekla tipa I), z 1 injekcijsko brizgo, 2 injekcijskima iglama in 1 čistilnim tamponom.
Caution must be exercised when administering Viraferon in combination with other potentially myelosuppressive agents. 
Pri sočasni uporabi zdravila Viraferon in drugih potencialno mielosupresivnih snovi priporočamo previdnost.